ARMGO Pharma Enrolls First Patient in Phase 2 Trial of ARM210 for the Treatment of Catecholaminergic Polymorphic Ventricular Tachycardia

FHS
July 21, 2023
11:04 am

Trial to investigate the safety and efficacy of ARM210 for the treatment of Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT).

MS Risk Linked to Ancient Migrations

Genetic risk for multiple sclerosis (MS) was brought into Europe by sheep and cattle herders migrating from the east approximately 5,000 years ago, DNA profiles

January 11, 2024

Cell donors are essential for new therapies. They need to be taken care of

Cutting-edge FDA-approved therapies made from human cells are now being used to treat cancer, diabetes, and other diseases. Currently, most approved cell-based therapies use an

July 24, 2024

Optum’s biosimilar business to exclude brand-name Stelara, Humira in 2025

Optum Rx is moving into the biosimilar business with a company it’s calling Nuvaila, and it’s starting out with biosimilars to AbbVie’s blockbuster rheumatoid arthritis

September 11, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.